XTX Topco’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
Other funds holding IKT
SCV
SCM
FFM
TECP
ACM
SL
CC
VCM
XTX Topco's IKT Position: Q1 2026 in Review
XTX Topco increased its Inhibikase Therapeutics (IKT) stake by 92% in Q1 2026, buying an estimated $33.1K and bringing the position to 38,914 shares worth $65.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3245.
XTX Topco first reported a position in IKT in Q4 2025 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.
- XTX Topco held 38,914 shares of Inhibikase Therapeutics worth $65.4K as of Q1 2026.
- XTX Topco bought 18,616 Inhibikase Therapeutics shares in Q1 2026, an estimated $33.1K.
- Inhibikase Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3245 holding.
- XTX Topco first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 2 quarters since.
- 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.
Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.